Prostanoid and leukotriene receptor (None standardized for the combined class; prostanoid receptors are abbreviated as DP, EP, FP, IP, TP; leukotriene receptors as BLT, CysLT, GPR17, etc.[1][3][5][6])

Prostanoid and leukotriene receptors are two distinct families of G protein-coupled receptors that mediate the biological actions of eicosanoids: prostanoids (including prostaglandins and thromboxanes) and leukotrienes. These receptors regulate a broad spectrum of physiological and pathological processes such as inflammation, pain, immune response, vascular tone, and smooth muscle function. Prostanoid receptors include DP, EP, FP, IP, and TP, with further subtypes (e.g., EP1–4), whereas leukotriene receptors are divided into BLT and CysLT classes (e.g., BLT1, CysLT1, CysLT2). Drugs targeting these receptors are widely used in the management of asthma, allergies, pain, and cardiovascular diseases[1][3][4][5][6][7].

Other names

Prostanoid receptor family (includes DP, EP, FP, IP, TP)Leukotriene receptor family (includes BLTR, CysLTR)Eicosanoid receptors (sometimes collectively used for both)

Antagonism of leukotriene receptors (reduces bronchoconstriction and inflammation) Agonism or antagonism of prostanoid receptors (modulates vascular tone, platelet aggregation, inflammation, and pain) Modulation of GPCR signaling pathways with downstream effects on cAMP, Ca²⁺, and phospholipase activity